← Figs overview

Figs vs Blue Sail Medical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Figs Inc (FIGS)

Q3 2026
▲3

FIGS raises 2026 outlook on strong Q2 and international surge

  • FIGS raises 2026 revenue and margin outlook after strong Q2 FIGS lifted its 2026 revenue growth forecast to about 20% from 14-16% and operating margin target to roughly 10.8%. Q2 revenue jumped 29% to $196.6 million, with active customers up 13% to 3.1 million. This positive guidance signals confidence and growth, pushing the stock up.

    This is the core new event that directly drives the stock higher.

  • International revenue surges 67%, expansion to 85 markets International revenue jumped 67% to $37.9 million, now 19% of total sales. FIGS expanded to 85 markets, adding 27 since year-end, and signed a partnership with Bupa Dental Care for nearly 400 UK dental centers. This broadens growth beyond the U.S., supporting the stock.

    Shows a key new growth driver that justifies the raised outlook.

  • Analyst upgrades and strong cash flow boost sentiment After Q2 earnings beat, Barclays and KeyBanc raised price targets to $20, implying 36% upside. FIGS generated $97 million in free cash flow over the past year and trades at 22 times that, which some see as cheap. Upgrades and cash generation attract buyers, lifting the stock.

    New analyst actions and cash flow metrics that influence investor perception.

  • Customs order blocks Jordan imports, but impact mitigated A U.S. Customs withhold release order blocks imports from FIGS' Jordan partner. Management says it has shifted production to other partners, mitigating most of the impact. While a risk, the mitigation limits the negative effect on the stock.

    A new regulatory risk that could hurt supply, but with limited impact.

August 2026
▲3

FIGS raises 2026 outlook on strong Q2 and international surge

  • FIGS raises 2026 revenue and margin outlook after strong Q2 FIGS lifted its 2026 revenue growth forecast to about 20% from 14-16% and operating margin target to roughly 10.8%. Q2 revenue jumped 29% to $196.6 million, with active customers up 13% to 3.1 million. This positive guidance signals confidence and growth, pushing the stock up.

    This is the core new event that directly drives the stock higher.

  • International revenue surges 67%, expansion to 85 markets International revenue jumped 67% to $37.9 million, now 19% of total sales. FIGS expanded to 85 markets, adding 27 since year-end, and signed a partnership with Bupa Dental Care for nearly 400 UK dental centers. This broadens growth beyond the U.S., supporting the stock.

    Shows a key new growth driver that justifies the raised outlook.

  • Analyst upgrades and strong cash flow boost sentiment After Q2 earnings beat, Barclays and KeyBanc raised price targets to $20, implying 36% upside. FIGS generated $97 million in free cash flow over the past year and trades at 22 times that, which some see as cheap. Upgrades and cash generation attract buyers, lifting the stock.

    New analyst actions and cash flow metrics that influence investor perception.

  • Customs order blocks Jordan imports, but impact mitigated A U.S. Customs withhold release order blocks imports from FIGS' Jordan partner. Management says it has shifted production to other partners, mitigating most of the impact. While a risk, the mitigation limits the negative effect on the stock.

    A new regulatory risk that could hurt supply, but with limited impact.

Latest
▲3

FIGS raises 2026 outlook on strong Q2 and international surge

  • FIGS raises 2026 revenue and margin outlook after strong Q2 FIGS lifted its 2026 revenue growth forecast to about 20% from 14-16% and operating margin target to roughly 10.8%. Q2 revenue jumped 29% to $196.6 million, with active customers up 13% to 3.1 million. This positive guidance signals confidence and growth, pushing the stock up.

    This is the core new event that directly drives the stock higher.

  • International revenue surges 67%, expansion to 85 markets International revenue jumped 67% to $37.9 million, now 19% of total sales. FIGS expanded to 85 markets, adding 27 since year-end, and signed a partnership with Bupa Dental Care for nearly 400 UK dental centers. This broadens growth beyond the U.S., supporting the stock.

    Shows a key new growth driver that justifies the raised outlook.

  • Analyst upgrades and strong cash flow boost sentiment After Q2 earnings beat, Barclays and KeyBanc raised price targets to $20, implying 36% upside. FIGS generated $97 million in free cash flow over the past year and trades at 22 times that, which some see as cheap. Upgrades and cash generation attract buyers, lifting the stock.

    New analyst actions and cash flow metrics that influence investor perception.

  • Customs order blocks Jordan imports, but impact mitigated A U.S. Customs withhold release order blocks imports from FIGS' Jordan partner. Management says it has shifted production to other partners, mitigating most of the impact. While a risk, the mitigation limits the negative effect on the stock.

    A new regulatory risk that could hurt supply, but with limited impact.

Blue Sail Medical Co Ltd (002382.CS)

Q3 2026
▲3▼1

Blue Sail swings to profit as glove prices recover and non-core unit sold

  • First-half profit turnaround confirmed Blue Sail expects H1 net profit of 90-110 million yuan, reversing last year's loss, and the interim report confirmed 95.7 million yuan. Both core units were profitable, with the health protection glove business swinging to a 250-300 million yuan profit on about 36% higher revenue. This is the main reason the stock has a positive story.

    The profit turnaround is the central new fact that answers why the stock is moving.

  • Glove prices lifted the whole sector Peer Zhonghong Medical forecast profit up 23-35 times, showing the health-glove industry is recovering through higher selling prices. Blue Sail benefits from the same trend. But since May raw material costs fell and nitrile glove prices were cut, so the boost may fade later this year.

    It shows the industry-wide force behind Blue Sail's profit and flags a fading tailwind.

  • Sale of Bikar raises cash and simplifies business Blue Sail completed the sale of its first-aid kit unit Bikar for 190 million yuan, receiving full payment. Bikar was only about 4% of revenue, so the main business is unaffected, while the cash strengthens the balance sheet and lets management focus on health protection and heart care.

    The completed divestment is a new capital event that improves cash and focus.

  • Headquarters costs and forex losses still weigh Despite operating profits, about 150 million yuan of headquarters costs cut attributable profit, including 50 million yuan of financing repurchase interest, 24 million yuan of convertible bond interest, and foreign exchange losses. The yuan's swings hurt both Blue Sail and peers, so reported profit stays far below the divisions' combined earnings.

    It is the real counterweight explaining why profit is much lower than divisional results.

August 2026
▲3▼1

Blue Sail swings to profit as glove prices recover and non-core unit sold

  • First-half profit turnaround confirmed Blue Sail expects H1 net profit of 90-110 million yuan, reversing last year's loss, and the interim report confirmed 95.7 million yuan. Both core units were profitable, with the health protection glove business swinging to a 250-300 million yuan profit on about 36% higher revenue. This is the main reason the stock has a positive story.

    The profit turnaround is the central new fact that answers why the stock is moving.

  • Glove prices lifted the whole sector Peer Zhonghong Medical forecast profit up 23-35 times, showing the health-glove industry is recovering through higher selling prices. Blue Sail benefits from the same trend. But since May raw material costs fell and nitrile glove prices were cut, so the boost may fade later this year.

    It shows the industry-wide force behind Blue Sail's profit and flags a fading tailwind.

  • Sale of Bikar raises cash and simplifies business Blue Sail completed the sale of its first-aid kit unit Bikar for 190 million yuan, receiving full payment. Bikar was only about 4% of revenue, so the main business is unaffected, while the cash strengthens the balance sheet and lets management focus on health protection and heart care.

    The completed divestment is a new capital event that improves cash and focus.

  • Headquarters costs and forex losses still weigh Despite operating profits, about 150 million yuan of headquarters costs cut attributable profit, including 50 million yuan of financing repurchase interest, 24 million yuan of convertible bond interest, and foreign exchange losses. The yuan's swings hurt both Blue Sail and peers, so reported profit stays far below the divisions' combined earnings.

    It is the real counterweight explaining why profit is much lower than divisional results.

Latest
▲3▼1

Blue Sail swings to profit as glove prices recover and non-core unit sold

  • First-half profit turnaround confirmed Blue Sail expects H1 net profit of 90-110 million yuan, reversing last year's loss, and the interim report confirmed 95.7 million yuan. Both core units were profitable, with the health protection glove business swinging to a 250-300 million yuan profit on about 36% higher revenue. This is the main reason the stock has a positive story.

    The profit turnaround is the central new fact that answers why the stock is moving.

  • Glove prices lifted the whole sector Peer Zhonghong Medical forecast profit up 23-35 times, showing the health-glove industry is recovering through higher selling prices. Blue Sail benefits from the same trend. But since May raw material costs fell and nitrile glove prices were cut, so the boost may fade later this year.

    It shows the industry-wide force behind Blue Sail's profit and flags a fading tailwind.

  • Sale of Bikar raises cash and simplifies business Blue Sail completed the sale of its first-aid kit unit Bikar for 190 million yuan, receiving full payment. Bikar was only about 4% of revenue, so the main business is unaffected, while the cash strengthens the balance sheet and lets management focus on health protection and heart care.

    The completed divestment is a new capital event that improves cash and focus.

  • Headquarters costs and forex losses still weigh Despite operating profits, about 150 million yuan of headquarters costs cut attributable profit, including 50 million yuan of financing repurchase interest, 24 million yuan of convertible bond interest, and foreign exchange losses. The yuan's swings hurt both Blue Sail and peers, so reported profit stays far below the divisions' combined earnings.

    It is the real counterweight explaining why profit is much lower than divisional results.